Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0MSAAI)
| ADC Name |
AVID100
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
AVID100
Click to Show/Hide
|
|||||
| Organization |
Forbius (Originator)
|
|||||
| Drug Status |
Phase 1/2 (discontinued)
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
MAB100
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
DM1
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
| Conjugate Type |
Random Lysines
|
|||||
| Combination Type |
emtansine
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
|||||
| Lung cancer |
1 Trials
|
|||||
| Breast cancer |
1 Trials
|
|||||
| Head and neck cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Inclusion criteria for Phase 1 involve patients with advanced/metastatic solid tumors refractory to standard therapy or ineligible for surgery, while Phase 2a targets specific EGFR-overexpressing cancers. Exclusion criteria for both phases include pregnancy, uncontrolled CNS metastases, significant comorbidities, and recent malignancies. Prohibited treatments encompass recent antineoplastic therapies, investigational drugs, radiotherapy, immunosuppressants, and strong CYP3A4 modifiers.
Click to Show/Hide
|
||||
| Administration Dosage |
No cycle 1 dose limiting toxicities (DLTs) have been observed in Cohorts 1-6 (dose (N); 20 (1), 40 (1), 80 (3), 120 (3), 180 (3), and 220 (3) mg/m2 every 3 weeks). Currently, patients are being evaluated in Cohort 7 (270 mg/m2; approximately 6.9 mg/kg).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03094169 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin | ||||
| Primary Endpoint |
The primary objectives include assessing the safety and tolerability of AVID100 in Phase 1a, focusing on abnormal lab values and adverse events, while Phase 2a evaluates preliminary antineoplastic effects based on objective response or stable disease.
|
||||
| Other Endpoint |
The PK profile of total antibody will be characterized over an 18-month period to understand its pharmacokinetic behavior.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Patients with advanced or metastatic epithelial malignancies.
|
||||
| Administration Dosage |
20, 40, 80, 120, 180, and 220 mg/m2 every 3 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03094169 | Clinical Status | Phase 1/2 | ||
| Clinical Description | Phase 1a/2a dose escalation trial to determine safety, tolerance, MTD, and preliminary antineoplastic activity of AVID100, in patients with advanced or metastatic solid tumors of epithelial origin. | ||||
References